Compare AbbVie Inc (ABBV) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Simon Property Group Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Simon Property Group Inc trades at $222.16 (market cap $73.68B). The key difference: AbbVie Inc is far larger — about 6.1× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.87%). Which is the better fit depends on your goals.
| ABBV | SPG | |
|---|---|---|
Market Cap | $449.91B | $73.68B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $227.56 |
52-Week Low | $184.85 | $159.93 |
Enterprise Value | $513.38B | $102.16B |
Dividend Yield | 2.72% | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Simon Property Group (SPG) trades at $227.19, up 0.5% on the day, with strong technical momentum as the stock approaches key resistance near $228. The REIT demonstrates robust fundamentals with Q1 2026 earnings beating expectations, revenue growth accelerating to $6.36B in 2025, and exceptional profitability metrics including 70.59% net income margin and 127.05% ROE. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering, while analyst sentiment remains mixed despite strong operational performance.
SPG presents a compelling investment case with premium mall assets generating strong cash flows and dividend income, though elevated valuation multiples and significant debt levels warrant caution. The stock's current price above the $211.30 consensus target suggests limited near-term upside, while e-commerce competition and interest rate sensitivity represent ongoing headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
